Value is a concept that concerns all healthcare stakeholders.
The duo hope to begin testing a new treatment within three years.
An editorial says the industry's use of terms like "low T" and "andropause" are false and misleading.
Regeneron's Eylea won its fourth indication; Sun Pharma wants to revive trust in its products; confidentiality agreements keep Amgen from telling patients their cancer risk
The drugmaker inks deal with Novo Nordisk to access its biologic discovery research platform.
Keytruda trial stopped due to positive results; new bill proposes continuing FDA rare pediatric voucher program; AstraZeneca signs five-year research pact with Harvard Stem Cell Institute
Delivering smarter dynamic communications rather than static timed communications based on self-reported data can help connect patients to information and support that drive brand loyalty and program success.
Nielsen data shows pharma spent $4.5 billion on DTC ads last year.
Mario Muredda and Mardene Miller will serve as co-presidents at the healthcare marketing agency.
Eleven new drugs with blockbuster potential are expected to launch this year; a bill would require FDA to quickly review drugs approved in the EU; Biogen reinforces its focus on hard-to-treat diseases
A judge rules against Amgen in Neupogen case; FDA advisory panel recommends Breio Ellipta for adults with asthma; AstraZeneca partners with Daiichi Sankyo to sell Movantik
An American Society of Clinical Oncology report shows the organization wants healthcare professionals to think in terms of value.
As global healthcare borders become increasingly blurred, the internationally mobile patient may become a standard patient segment considered in healthcare market research.
The Paris-based drugmaker's global president of R&D said that jumping through different and inconsistent regulatory hoops puts an "enormous" cost on drugmakers.
A Florida Congressman introduced a bill that would expand patent protections; Novo Nordisk expects to increase diabetes medication prices; AbbVie expanded its Alzheimer's research
Oncology and diabetes medications are expected to be major areas of growth.
At SXSW, for the first time, health wasn't a breakout topic, but rather a "break-in" topic that had the attention of just about every presenter and attendee.
The drugmaker, which markets the Dimetapp cough and cold line, sent a complaint to the Better Business Bureaus.
GlaxoSmithKline respiratory drug's safety profile will be evaluated by FDA advisory panel; Actavis axes 400 New York jobs; physician testifies that he falsified Diovan clinical trial data
The personal genetics company created a therapeutics group to extricate new drug targets from its research database.
Traditional tactics of connecting with physicians are quickly becoming obsolete.
Increased FDA scrutiny has not garnered trust for the new medications.
Interim results show cancer drug Imbruvica works well with other treatments; two studies show pricey new HCV medications are cost effective; the American College of Physicians wants less cardiac testing
The approval follows three advisory panel reviews and a complete response letter.
New data suggest Amgen's PCSK9 may reduce risks of heart attacks, Salix bidding is war too rich for Endo's blood, Actavis bipolar drug use is expanded to 10- to 17-year-olds.
J&J sues GlaxoSmithKline over Flonase ads, CDC report finds patients with invasive cancer are living for five years or longer have diagnosis, and Bristol-Myers Squibb resubmits its HCV treatment.
The research will be released as pharmacy benefit managers raise concerns about the potential costs of PCSK9 inhibitors.
The CMO of CVS Health said biosimilars could drive down prices 10% to 20% lower than current investor expectations.
The company argues its offer for Salix is superior to the terms offered by serial acquirer Valeant.
The partners will focus on developing treatments for metabolic disorders.
Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.
- US pharma market value projected to be $550 billion in five years
- Biosimilar uptake will require companies to tell a trustworthy backstory
- Lawmakers propose allowing pharma companies to share some off-label information
- Apple's ResearchKit: Five Guidelines for Pharma
- Everyday Health buys rare-disease agency Cambridge BioMarketing